ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) is a 10-year cooperative agreement with the U.S. Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
Successful HIV prevention requires increased contribution to research efforts by those countries and regions hardest hit by the epidemic
This visionary US$340+ million program is part of IAVI’s ongoing 22-year collaboration with USAID that has significantly advanced HIV vaccine R&D while accelerating the search for innovative biomedical prevention tools, including a safe and globally effective HIV vaccine. USAID’s long-term investment and willingness to foster advances in science to benefit the world’s most at-risk populations — men who have sex with men, people who inject drugs, sex workers, transgender women, and adolescent girls and young women — have enabled IAVI’s unique model in Africa and India. Sub-Saharan Africa remains the region most severely affected, with 25 million adults and children living with HIV and AIDS and where researchers find the most genetically diverse HIV subtype infections.
ADVANCE framework
Goal: Safe and globally effective HIV vaccine and biomedical prevention products developed with leadership by African and Indian stakeholders that are available and accessible for populations at risk of infection.
A unique model of worldwide collaboration
The ADVANCE partner network includes state-of-the-art African and Indian clinical research centers, and extensive laboratory and research capabilities are available including the IAVI-Human Immunology Laboratory, based at Imperial College London; the IAVI Neutralizing Antibody Center, based at Scripps Research in La Jolla, California; and the HIV Vaccine Translational Research Laboratory at the Translational Health Science and Technology Institute, based in Faridabad, Haryana, India.
Partnership is key to ADVANCE success
The ADVANCE CRC partner network drives regional collaboration, capacity strengthening, and research to test promising HIV vaccine candidates and biomedical prevention products, while seeking a clearer understanding of the epidemic in Africa and India. ADVANCE links African and Indian researchers with global collaborators and innovative technologies throughout all stages of HIV vaccine and biomedical discovery, design, and development — including access to key populations; community engagement; laboratory, manufacturing, pharmacy, data management, regulatory, quality assurance and training functions; and vital efficacy trial experience to test whether a vaccine or biomedical prevention product demonstrates a health benefit over a placebo or other intervention.
ADVANCE – IAVI in partnership with:
Africa
- Aurum Institute
- Center for Family Health Research (Rwanda)
- Center for Family Health Research (Zambia)
- KAVI Institute of Clinical Research
- Kenya Medical Research Institute-Wellcome Trust Research Programme
- Medical Research Council/Uganda Virus Research Institute – London School of Hygiene and Tropical Medicine
- National Institute for Communicable Diseases
- Uganda Virus Research Institute–IAVI
- University of KwaZulu-Natal, HIV Pathogenesis Programme
Indo-Africa
- Government Hospital of Thoracic Medicine
- Indira Gandhi Institute of Child Health
- National AIDS Research Institute
- Y.R. Gaitonde Centre for AIDS Research and Education
Read more about the ADVANCE partnership that will run until June 2026:
Contributing to HIV Vaccine Research in Africa: USAID-Funded Science Capacity Building Partnership with IAVI
